VOLL MARK 4

What Happened

• Mark Voll, Chief Financial Officer of RenovoRx, was granted an aggregate 80,000 restricted stock units (RSUs) reported on Apr 3, 2026. The Form 4 lists the acquisition price as $0.00 (typical for RSU grants); the economic value will depend on RNXT’s share price when RSUs vest or convert to shares.
• The 80,000 RSUs break down as: 8,777 RSUs for February 2026 service (fully vested on grant), 12,270 RSUs for March 2026 service (fully vested on grant), and 58,953 RSUs granted for future service subject to monthly vesting. No cash was paid for the award.

Key Details

• Transaction date: 2026-04-03; Filing date: 2026-04-07 (filed after the reported transaction date; this exceeds the typical 2-business-day Form 4 filing window).
• Reported acquisition: 80,000 RSUs at $0.00 (total reported cost $0.00).
• Immediate vesting: 8,777 + 12,270 = 21,047 RSUs vested upon grant; 58,953 RSUs vest monthly for future service.
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: RSUs for future service are “valued based on the closing price on the last trading day of the month in which the services were performed” (per filing).

Context

• RSU awards are compensation, not open-market purchases or sales. Grants reported at $0 on Form 4 reflect the grant event; realized value depends on future stock price at vesting or conversion.
• Immediate vesting of the February and March RSUs means those portions are no longer contingent on future service; the larger portion remains subject to monthly vesting and will convert to shares over time.